Oculis SA’s $57 Million Series C Financing Round

Vischer advised Oculis SA on the deal, while Walder Wyss advised Hyfinity Investments. Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to…

This content is for Standard 1 Year members only.
Login Join Now
Federica Tiefenthaler

Author: Federica Tiefenthaler

This content is for Standard 1 Year members only.
Login Join Now